NCT05975463

Hepatic Artery Infusion of Adebrelimab Combined With Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma With Failure of Systemic Therapy Combined With Interventional Therapy

Prospective Single Arm, Single Center, Phase II Clinical Study of Hepatic Artery Infusion of Adebrelimab Combined With Bevacizumab Treatment System for Advanced Hepatocellular Carcinoma With Failure of Systemic Therapy Combined With Interventional Therapy

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: HuiKai Li · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this prospective single arm, Phase II Clinical Study is to explore and evaluate the efficacy and safety of hepatic artery infusion of Adebrelimab combined with Bevacizumab in the treatment of patients with advanced hepatocellular carcinoma who failed in systematic therapy combined with interventional therapy. Participants will receive hepatic artery infusion of Adebrelimab 1200mg, d1, q3w, combined with hepatic artery infusion of Bevacizumab 5mg/kg, d1, q3w, HAIC treatment for 3-4 times.

Conditions

• Hepatocellular Carcinoma

Interventions

Type	Name	Description
PROCEDURE	HAIC	hepatic artery infusion for 3-4 times.
DRUG	Adebrelimab	hepatic artery infusion of Adebrelimab 1200mg, d1, q3w，for 3-4 times.
DRUG	Bevacizumab	hepatic artery infusion of Bevacizumab 5mg/kg, d1, q3w, for 3-4 times.

Timeline

• Start date: 2023-09-15
• Primary completion: 2025-07-31
• Completion: 2026-07-31
• First posted: 2023-08-04
• Last updated: 2023-09-01

Locations

1 site across 1 country: China